<DOC>
	<DOCNO>NCT02271126</DOCNO>
	<brief_summary>The best anticoagulation strategy Extracorporeal Membrane Oxygenation ( ECMO ) unknown . Actual recommendation suggest use unfractionated heparin infusion monitor effect either activate Partial Thromboplastin Time ( aPTT ) Activated Clotting Time ( ACT ) . Since hemorrhage still major adverse effect ECMO impact mortality morbidity , investigator raise question whether alternative monitoring technique namely Thromboelastography ( TEG ) could allow accurate management anticoagulation set . To test hypothesis investigator design pilot study test safety feasibility anticoagulation monitor algorithm base TEG versus aPTT .</brief_summary>
	<brief_title>TEG Anticoagulation Monitoring During ECMO</brief_title>
	<detailed_description>Extracorporeal membrane oxygenation ( ECMO ) frequently use supportive tool setting acute severe respiratory and/or circulatory failure . The presence extracorporeal circuit oxygenator bring along need anticoagulate patient order prevent activation coagulation cascade lead thrombosis artificial surface loss coagulation factor , fibrinogen platelet . Despite tight monitoring different anticoagulation essay bleed remain main threat patient ECMO , leave thrombosis anecdotic event . In institution , anticoagulation ECMO monitor mainly aPTT ratio range 1.5 2 ( patient normal ) . Recently , investigator start match Thromboelastography ( TEG ) assay activate Partial Thromboplastin Time ( aPTT ) Activated Clotting Time ( ACT ) routine measurement ECMO . Data preliminary analysis thirty-two patient show nearly half TEG assay , R ( reaction time ) parameter sensitive inhibition fibrin formation heparin , consistently prolong despite aPTT ACT normal range . In patient investigator register high rate bleeding ( nearly 40 % patient suffer clinically significant bleeding , i.e . bleeding required heparin dose reduction , blood transfusion interruption extracorporeal support ) . These finding suggest possibility actual target aPTT ratio might overrate . The purpose study test safety feasibility standardize protocol base TEG versus current practice ( aPTT ) manage anticoagulation ECMO . 40 consecutive adult patient undergo ECMO randomize either TEG-driven anticoagulation group aPTT-driven group . Written inform consent obtain accord national legislation . In group , patient connect ECMO , heparin bolus 50-70 UI/kg ( depend baseline aPTT value ) administer follow continuous infusion 18 UI/kg/h start ; first 12 hour thereafter proper anticoagulation level monitor Activated Clotting Time ( ACT , therapeutic range 180-210 second , perform every 1 2 hour accord standardized protocol ) . From thirteenth hour onwards group follow either aPTT monitoring TEG accord randomization . Every morning group aPTT , TEG , Antithrombin anti-Factor Xa activity assess . - aPTT-driven group : aPTT ratio target 1.5 - 2.0 actual clinical practice ; frequency aPTT measurement may vary minimum 3 time per day maximum 6 depend standardize protocol . When aPTT value fall well desired range heparin bolus administer . When high , infusion stop either 30 60 minute . - TEG-driven group : target range R parameter Kaolin activated-TEG ( R K-TEG ) 16 - 24 minute ; frequency TEG assay may vary minimum 3 time per day maximum 6 depend standardize protocol . When TEG value fall well desired range heparin bolus administer , high infusion stop either 30 60 minute . Daily management require haemoglobin , platelet , PT ratio , D-dimer fibrinogen check 2 3 time daily , maintain specific value ( Hb &gt; 10 g/dl ; PLT &gt; 45.000/mm3 ; Fibrinogen &gt; 150 mg/dl ; Antithrombin activity &gt; 70 % ; PT ratio &gt; 1.5 ) haemocomponents transfusion . Data patient collect daily basis : laboratory exam , hemodynamic status , transfusion , surgery invasive intervention , extracorporeal lung performance . End study ECMO discontinuation , deep vein thrombosis patient ' cannulation site assess doppler ultrasound .</detailed_description>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Thromboplastin</mesh_term>
	<criteria>All patient initiate ECMO support acute respiratory failure centre equipe another centre screen eligibility . Patients age 18 , proven Heparininduced Thrombocytopenia platelets count le 30.000/mm3 exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>ECMO</keyword>
	<keyword>Heparin</keyword>
	<keyword>Thromboelastography</keyword>
	<keyword>Bleeding complication</keyword>
</DOC>